SAGE Sage Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SAGE

Price (delayed)

$13.62

Market cap

$819.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.39

Enterprise value

$647.5M

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing ...

Highlights
The company's debt has shrunk by 68% YoY and by 36% QoQ
The net income has increased by 10% year-on-year and by 7% since the previous quarter
SAGE's quick ratio is up by 17% QoQ but it is down by 13% YoY
SAGE's equity is down by 38% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sagerx.com
Peers: EGRX RGLS CPRX CORT

Key stats

What are the main financial stats of SAGE
Market
Shares outstanding
60.18M
Market cap
$819.68M
Enterprise value
$647.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
8.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.11
Earnings
Revenue
$91.06M
EBIT
-$503.14M
EBITDA
-$501.74M
Free cash flow
-$425.06M
Per share
EPS
-$8.39
Free cash flow per share
-$7.07
Book value per share
$11.74
Revenue per share
$1.51
TBVPS
$12.76
Balance sheet
Total assets
$767.6M
Total liabilities
$61.8M
Debt
$3.31M
Equity
$705.8M
Working capital
$693.64M
Liquidity
Debt to equity
0
Current ratio
12.22
Quick ratio
11.82
Net debt/EBITDA
0.34
Margins
EBITDA margin
-551%
Gross margin
96.5%
Net margin
-552.5%
Operating margin
-595.2%
Efficiency
Return on assets
-54.7%
Return on equity
-60.9%
Return on invested capital
-71.6%
Return on capital employed
-71.3%
Return on sales
-552.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SAGE stock price

How has the Sage Therapeutics stock price performed over time
Intraday
3.89%
1 week
-0.51%
1 month
-20.58%
1 year
-71.3%
YTD
-37.15%
QTD
-27.32%

Financial performance

How have Sage Therapeutics's revenue and profit performed over time
Revenue
$91.06M
Gross profit
$87.87M
Operating income
-$542.06M
Net income
-$503.14M
Gross margin
96.5%
Net margin
-552.5%
The company's net margin has surged by 91% YoY and by 12% QoQ
Sage Therapeutics's operating margin has surged by 90% YoY and by 11% QoQ
The net income has increased by 10% year-on-year and by 7% since the previous quarter
Sage Therapeutics's operating income has increased by 7% from the previous quarter and by 6% YoY

Growth

What is Sage Therapeutics's growth rate over time

Valuation

What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
1.16
P/S
8.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.11
Sage Therapeutics's EPS has increased by 10% YoY and by 7% from the previous quarter
The P/B is 57% less than the 5-year quarterly average of 2.6 and 41% less than the last 4 quarters average of 1.9
SAGE's equity is down by 38% YoY and by 12% from the previous quarter
SAGE's P/S is 98% below its 5-year quarterly average of 549.3 and 91% below its last 4 quarters average of 101.7
The revenue has increased by 5% from the previous quarter

Efficiency

How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROS has soared by 91% YoY and by 12% from the previous quarter
The ROIC has contracted by 46% YoY and by 6% from the previous quarter
Sage Therapeutics's ROE has decreased by 44% YoY and by 5% from the previous quarter
SAGE's ROA is down by 39% year-on-year and by 4.4% since the previous quarter

Dividends

What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SAGE.

Financial health

How did Sage Therapeutics financials performed over time
The total assets has declined by 37% year-on-year and by 13% since the previous quarter
Sage Therapeutics's total liabilities has decreased by 29% YoY and by 25% QoQ
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The company's debt has shrunk by 68% YoY and by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.